31 Aug 2023 13:00
31 August 2023
Physiomics plc
("Physiomics" or "the Company")
Contract Award
Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded its first contract with a new UK-based biotech client. The contract, which has a value of £125,000 and relates to a project in the immune-oncology field, is expected to be completed within this calendar year.
Physiomics CEO, Dr Jim Millen, commented:
"We are delighted to have been chosen by this new client to support the development of its lead asset. We look forward to working with them on this exciting project."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 40 targets and 70 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
Physiomics (PYC)